LOG IN
SIGN UP
MARKET
HROW
HROW
Harrow Health Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
6.82
+0.32
+4.92%
After Hours: 6.82 0 0.00% 16:00 05/26 EDT
OPEN
6.56
PREV CLOSE
6.50
HIGH
6.98
LOW
6.56
VOLUME
48.19K
TURNOVER
0
52 WEEK HIGH
12.99
52 WEEK LOW
5.40
MARKET CAP
184.35M
P/E (TTM)
-8.7402
1D
5D
1M
3M
1Y
5Y
BRIEF-Harrow Health Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
reuters.com · 5h ago
Harrow Health files for $300M mixed shelf offering
Harrow Health (NASDAQ:HROW) has filed for a $300M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends
Seekingalpha · 7h ago
--B. Riley Raises Harrow Health's Price Target to $20 from $17 After Higher-than-Expected Q1 Revenue, Keeps Buy Rating
MT Newswires · 6d ago
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Is Harrow Health, Inc.'s (NASDAQ:HROW) Shareholder Ownership Skewed Towards Insiders?
Every investor in Harrow Health, Inc. ( NASDAQ:HROW ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 05/06 13:01
Harrow Health Non-GAAP EPS of $0.03 beats by $0.07, revenue of $22.12M beats by $2.64M
Harrow Health press release (NASDAQ:HROW): Q1 Non-GAAP EPS of $0.03 beats by $0.07. Revenue of $22.12M (+43.3% Y/Y) beats by $2.64M.
Seekingalpha · 05/05 21:03
Harrow Health Q1 EPS $0.03 Beats $(0.03) Estimate, Sales $22.10M Beat $19.48M Estimate
Harrow Health (NASDAQ:HROW) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.03) by 200 percent. This is a 200 percent increase over earnings of $0.01 per share from the
Benzinga · 05/05 20:38
-- Earnings Flash (HROW) HARROW HEALTH Reports Q1 EPS $0.03, vs. Street Est of $-0.05
MT Newswires · 05/05 16:27
No Data
Learn about the latest financial forecast of HROW. Analyze the recent business situations of Harrow Health Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 4 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HROW stock price target is 17.38 with a high estimate of 20.00 and a low estimate of 16.00.
Current 6.82
EPS
Actual
Estimate
-0.25-0.19-0.12-0.06
Institutional Holdings
Institutions: 102
Institutional Holdings: 16.30M
% Owned: 60.28%
Shares Outstanding: 27.03M
TypeInstitutionsShares
Increased
23
719.38K
New
10
167.09K
Decreased
26
786.40K
Sold Out
7
63.70K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.31%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Chairman/Chief Executive Officer/Director
Mark Baum
Chief Financial Officer/Secretary
Andrew Boll
Corporate Executive
John Saharek
Director
Richard Lindstrom
Independent Director
Martin Makary
Independent Director
Teresa Sparks
Independent Director
Perry Sternberg
Independent Director
R. Lawrence Van Horn
No Data
No Data
About HROW
Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. The Company holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical stage drug candidates, which are being developed by Surface Ophthalmics and Melt Pharmaceuticals.
Webull offers kinds of Harrow Health Inc stock information, including NASDAQ:HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.